Document is current

Article History

Received: 26 October 2016

Accepted: 28 November 2017

First Online: 21 December 2017

Ethics approval and consent to participate

: The study protocol was approved by the RAND Human Subjects Protection Committee (HSPC). HSPC-approved information sheets which contained all elements of informed consent preceded electronic and paper surveys; completion of the electronic survey indicated “electronic consent” and completion of the paper survey indicated “implied” consent. No individual patient data are reported.

: Not applicable.

: Financial competing interests.The authors are employees of The RAND Corporation (“RAND”), a nonprofit institution that helps improve policy and decisionmaking through research and analysis. Within the past 3 years, RAND has received funding for research projects from Alkermes plc (“Alkermes”) relating to the pharmaceutical Vivitrol, which is manufactured and sold by Alkermes. Allison Ober participated in RAND research projects funded by Alkermes. Katherine Watkins participated in RAND research projects funded by Alkermes and served as Principal Investigator. To the extent that this paper suggests a benefit related to greater provider acceptance of Vivitrol, this finding may have a positive financial effect on Alkermes. Prior to submission, RAND conducted additional internal quality reviews of this article with a particular focus on the possibility of bias.Alkermes provided Vivitrol at no charge to certain patients participating in this study. This arrangement was disclosed and approved by the National Institutes of Health project officer.Non-financial competing interests.Not applicable.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.